SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 30th, 2020 • Kannalife Inc • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 19, 2020, by and between KANNALIFE, INC., a Delaware corporation, with headquarters located at 3805 Old Easton Road, Doylestown, PA 18902 (the “Company”), and ___________, with its address at ______________ (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 18th, 2020 • Kannalife Inc • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 12, 2020, by and between KANNALIFE, INC., a Delaware corporation, with its address at 3805 Old Easton Road, Doylestown, PA 18902 (the “Company”), and _______________, with its address at ____________________ (the “Buyer”).
COMMON STOCK PURCHASE WARRANT KANNALIFE, INC.Common Stock Purchase Warrant • June 11th, 2020 • Kannalife Inc • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of purchase price of $52,000.00, for the first tranche of $55,000.00 under the convertible promissory note in the principal amount of $165,000.00 issued by the Company (as defined below) to the Holder (as defined below) on June 2, 2020) (the “Note”)),_________________ (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Kannalife, Inc., a Delaware corporation (the “Company”), 36,666 shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant).
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • September 22nd, 2020 • Kannalife Inc • Pharmaceutical preparations • Delaware
This equity purchase agreement is entered into as of September 18, 2020 (this "Agreement"), by and between Kannalife, Inc., a Delaware corporation (the "Company"), and Cross & Company, a Nevada corporation (the "Investor").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 11th, 2020 • Kannalife Inc • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 2, 2020, by and between KANNALIFE, INC., a Delaware corporation, with headquarters located at 3805 Old Easton Road, Doylestown, PA 18902 (the “Company”), and _______________________ , with its address at _________________ (the “Buyer”).
APPLICATION DEVELOPMENT AGREEMENTApplication Development Agreement • June 22nd, 2016 • TYG Solutions Corp. • Services-prepackaged software • New York
This Mobile Application Development Agreement (the “Agreement”) is entered into as of February 24, 2015, by and between TYG Solutions Corp (the “Developer”) with an address at 202 Ave F. Brooklyn NY, 11218 and Mobile NC (the “Company”) with an address at 160-10 89th St. Queens NY, 11432.
COMMON STOCK PURCHASE WARRANT (WARRANT __) KANNALIFE, INC.Common Stock Purchase • June 30th, 2020 • Kannalife Inc • Pharmaceutical preparations • Nevada
This COMMON STOCK PURCHASE WARRANT (WARRANT A) (the “Warrant”) certifies that, for value received (in connection with the issuance of the $150,000.00 convertible promissory note to the Holder (as defined below) of even date) (the “Note”), _____________ (including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to purchase from Kannalife, Inc., a Delaware corporation (the “Company”), up to 115,385 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated June 19, 2020, by and among the Company and the Holder (the “Purchase Agreement
WARRANT TO PURCHASE COMMON STOCK of NEUROPATHIX, INC.Neuropathix, Inc. • February 23rd, 2021 • Pharmaceutical preparations • Pennsylvania
This Warrant to Purchase Common Stock of Neuropathix, Inc. (this “Warrant”), is issued to Lyons Capital LLC (and, together with its permitted successors and assigns, the “Holder”) by Neuropathix, Inc., a Delaware corporation (the “Company”). This Warrant is issued as part of a series of similar warrants (the “Warrants”) issued to the Holder.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 31st, 2018 • TYG Solutions Corp. • Services-prepackaged software • Pennsylvania
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), dated as of July 25, 2018 (the “Effective Date”), is entered into by and between TYG Solutions Corp., a Delaware corporation (the “Company”), and Mark Corrao (“Executive”).
Weinberg & Baer LLCTYG Solutions Corp. • February 11th, 2015 • Services-prepackaged software
We have issued our report dated July 28, 2014, with respect to the financial statements of TYG Solutions Corp. as of June 30, 2014 and December 31, 2013 and for the six months ended June 30, 2014 and the period from inception (March 25, 2013) through December 31, 2013 contained in the Registration Statement and Prospectus of TYG Solutions Corp. on Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
LOCK-UP AND LEAK-OUT AND RELEASE AGREEMENTLock-Up and Leak-Out and Release Agreement • July 31st, 2018 • TYG Solutions Corp. • Services-prepackaged software • California
This Lock-Up and Leak-Out and Release Agreement (the “Agreement”) is entered into by and between TYG Solutions, Corp., a Delaware corporation (the “Company”), Kannalife Sciences, Inc., a Delaware corporation (“Kannalife”) and those Kannalife stockholders that have executed this Agreement, the Share Exchange Agreement (as defined below) and any other documents required by the Company related to this Agreement and the Share Exchange Agreement (each a “Participating Stockholder”), with reference to the following facts:
Weinberg & Baer LLCTYG Solutions Corp. • May 5th, 2016 • Services-prepackaged software
We have issued our report dated March 2, 2016,except for Note 6, as to which the date is May 4, 2016, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
March 12, 2020 Securities Transfer Corporation Plano, Texas 75093Kannalife Inc • March 18th, 2020 • Pharmaceutical preparations
Kannalife, Ind., a Delaware corporation (the "Company"), and _________ (the “Investor”) have entered into a Securities Purchase Agreement dated as of March 12, 2020 (the “Agreement”) providing for the issuance of the Convertible Promissory Note in the principal amount of $105,000.00 dated March 12, 2020 (the “Note”).
Weinberg & Baer LLCTYG Solutions Corp. • March 22nd, 2016 • Services-prepackaged software
We have issued our report dated March 2, 2016, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
Weinberg & Baer LLCTYG Solutions Corp. • October 23rd, 2015 • Services-prepackaged software
We have issued our report dated July 28, 2014, with respect to the financial statements of TYG Solutions Corp. as of June 30, 2014 and December 31, 2013 and for the six months ended June 30, 2014 and the period from inception (March 25, 2013) through December 31, 2013 contained in the Registration Statement and Prospectus of TYG Solutions Corp. on Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT - EXCLUSIVE COVER PAGEPatent License Agreement • December 28th, 2018 • Kannalife Inc • Pharmaceutical preparations • District of Columbia
Weinberg & Baer LLCTYG Solutions Corp. • June 22nd, 2016 • Services-prepackaged software
We have issued our report dated March 2, 2016,except for Note 6, as to which the date is May 4, 2016, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
INTELLECTUAL PROPERTY RIGHTS PURCHASE AND TRANSFER AGREEMENTIntellectual Property Rights Purchase and Transfer Agreement • December 21st, 2020 • Neuropathix, Inc. • Pharmaceutical preparations • Delaware
This Intellectual Property Rights Purchase and Transfer Agreement (this “IP Purchase Agreement” or “Agreement”) is effective this 17th day of December 2020, by and between Advanced Neural Dynamics, Inc. (“AND”) located at the Pennsylvania Biotechnology Center (“PBC”) at 3805 Old Easton Road, Doylestown, PA 18902; and Fox Chase Chemical Diversity Center, Inc. (“FOX”) located at the PBC at 3805 Old Easton Road, Doylestown, PA 18902; Douglas Brenneman, Ph.D, located at 121 Kingston Way, North Wales, PA 19454 (“Brenneman”), (collectively, “TRANSFERORS”) and Neuropathix, Inc., a Delaware corporation (“NPTX”) (hereinafter, “Acquiror” or “NPTX”). Each of Transferor and the Acquiror shall be referred to separately herein as a “Party” and together as the “Parties.”
SETTLEMENT AND MUTUAL RELEASE AGREEMENTSettlement and Mutual Release Agreement • December 28th, 2018 • Kannalife Inc • Pharmaceutical preparations • California
This Settlement and Mutual Release Agreement (hereinafter "Agreement") is entered into and made effective as of July 15, 2017 (the "Effective Date") by and between Karmalife Sciences, Inc., a Delaware corporation ("KLSI") and Karma Botanicals, Inc., a Delaware corporation ("Karma Botanicals") on the one hand, and General Hemp, LLC, a Delaware limited liability company ("General Hemp") and Kannaway LLC, a Nevada limited liability company, formerly a wholly-owned subsidiary of General Hemp ("Kannaway") on the other hand. KLSI, Kanna Botanicals, General Hemp and Kannaway are sometimes referred to as the "parties," each a "party," and/or "undersigned parties" with respect to the following.
8% Junior Unsecured Convertible NoteKannalife Inc • March 30th, 2020 • Pharmaceutical preparations • New Jersey
This 8% Junior Unsecured Convertible Note (the “Note”) is duly authorized and issued by Kannalife, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”), having its principal place of business located at 3805 Old Easton Road, Doylestown, PA 18902. This Note is one of a series of junior unsecured convertible notes of the Company, of like tenor and kind, in the aggregate principal amount of not more than $3,000,000 being issued by the Company contemporaneously with this Note (such notes other than this Note being hereinafter referred to as the “Other Notes”).
NEUROPATHIX, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 23rd, 2021 • Neuropathix, Inc. • Pharmaceutical preparations • Pennsylvania
This Common Stock Purchase Agreement (this “Agreement”), dated as of February 17, 2021, but for all purposes shall be effective as of February 10, 2021 (the “Effective Date”), is entered into by and between Neuropathix, Inc., a Delaware corporation (the “Company”), and Lyons Capital LLC (the “Investor”).
Weinberg & Baer LLCTYG Solutions Inc. • August 21st, 2014
We have issued our report dated July 28, 2014, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
Weinberg & Baer LLCTYG Solutions Corp. • February 11th, 2015 • Services-prepackaged software
We have issued our report dated July 28, 2014, with respect to the financial statements of TYG Solutions Corp. as of June 30, 2014 and December 31, 2013 and for the six months ended June 30, 2014 and the period from inception (March 25, 2013) through December 31, 2013 contained in the Registration Statement and Prospectus of TYG Solutions Corp. on Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
KANNALIFE, INC.Kannalife Inc • June 30th, 2020 • Pharmaceutical preparations
KANNALIFE, INC.Kannalife Inc • June 11th, 2020 • Pharmaceutical preparations
Weinberg & Baer LLCTYG Solutions Corp. • May 19th, 2016 • Services-prepackaged software
We have issued our report dated March 2, 2016,except for Note 6, as to which the date is May 4, 2016, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
NATIONAL INSTITUTE OF HEALTH PATENT LICENSE AGREEMENT – NONEXCLUSIVE COVER PAGEPatent License Agreement • December 28th, 2018 • Kannalife Inc • Pharmaceutical preparations • District of Columbia
PHARMACEUTICAL ROYALTY AGREEMENTPharmaceutical Royalty Agreement • December 21st, 2020 • Neuropathix, Inc. • Pharmaceutical preparations • Pennsylvania
This Pharmaceutical Royalty Agreement dated as of December 17, 2020 (the “Royalty Agreement”) is made by and between Neuropathix, Inc., (“NPTX”) a Delaware corporation, having its principal place of business at 3805 Old Easton Road, Doylestown, PA 18902; and Fox Chase Chemical Diversity Center, Inc. (“FOX”) located at the PBC at 3805 Old Easton Road, Doylestown, PA 18902; and Advanced Neural Dynamics, Inc. (“AND”) located at the Pennsylvania Biotechnology Center (“PBC”) at 3805 Old Easton Road, Doylestown, PA 18902, collectively (the “INVENTORS”)
LOCK-UP AND LEAK-OUT AND RELEASE AGREEMENTLock-Up and Leak-Out and Release Agreement • July 31st, 2018 • TYG Solutions Corp. • Services-prepackaged software • California
This Lock-Up and Leak-Out and Release Agreement (the "Agreement") is entered into by and between TYG Solutions, Corp., a Delaware corporation (the "Company"), Kannalife Sciences, Inc., a Delaware corporation ("Kannalife") and those Kannalife stockholders that have executed this Agreement, the Share Exchange Agreement (as defined below) and any other documents required by the Company related to this Agreement and the Share Exchange Agreement (each a "Participating Stockholder"), with reference to the following facts:
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • July 31st, 2018 • TYG Solutions Corp. • Services-prepackaged software • Delaware
This Share Exchange Agreement, dated as of July 25, 2018 (this “Agreement”), is made and entered into by and among TYG Solutions Corporation, a Delaware corporation (“TYYG” or the “Company”) on the one hand; and Kannalife Sciences, Inc., (“Kannalife”) a Delaware corporation and the Stockholders of Kannalife listed on Exhibit A attached hereto (each, a “Kannalife Stockholder” and collectively the “Kannalife Stockholders”) that meet the requirements of eligibility and participate in the Share Exchange (as hereinafter defined), on the other hand.
Weinberg & Baer LLCTYG Solutions Corp. • April 13th, 2016 • Services-prepackaged software
We have issued our report dated March 2, 2016, with respect to the financial statements of TYG Solutions Corp. contained in the Registration Statement and Prospectus of TYG Solutions Corp. on amended Form S-1. We hereby consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the heading “Experts.”
